Boehringer Ingelheim, a leading research-driven biopharmaceutical company, has been lifted to 8th place in the 2024 Access to Medicine Index (ATMI), up from 13th in 2022. This improvement reflects the company’s strategic shift of prioritizing Health Equity as its primary contribution to the United Nations Sustainable Development Goals (UN SDGs). Every two years the ATMI [...]
OSS, The Netherlands, Nov. 19, 2024 (Korea Bizwire) – Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlands, and Sweden, announces the full Good Manufacturing Practice (GMP) approval of its expanded nanomedicine facility in Oss. Granted by the Dutch Healthcare Authority, the approval enables GMP manufacturing [...]
REGULATED INFORMATION November 19, 2024, 7:00am CET / 1:00am ET NYXOAH SA (Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (hereinafter the “Company”) Invitation to attend the special shareholders’ meeting of the Company to be held on December 19, 2024 The board of directors of the Company is pleased to invite its securities [...]
SHANGHAI, Nov. 16, 2024 (Korea Bizwire) – Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, and its wholly-owned subsidiary, TopAlliance Biosciences Inc. (TopAlliance Biosciences), announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved [...]
Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD) One of several biosimilar value drivers for Sandoz Sandoz remains committed to accelerating patient access by strengthening its biosimilar portfolio, reinforcing global and European leadership Basel, November 15, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced [...]
ST. LOUIS, Nov. 13, 2024 (Korea Bizwire) – Curium, a world leader in nuclear medicine, announced today that its ECLIPSE trial met its primary endpoint. ECLIPSE is a pivotal Phase 3, multi-center, open-label, randomized clinical trial comparing the safety and efficacy of 177Lu-PSMA-I&T (INN: lutetium (177Lu) zadavotide guraxetan) versus hormone therapy in patients with metastatic castration-resistant [...]
Propelling the Next Phase of Innovation in Chronic Wound Management DEBx Medical is poised for accelerated growth in chronic wound solutions, bolstered by the second round of investment by TVM Capital Healthcare. AMSTERDAM and DUBAI, United Arab Emirates, Nov. 13, 2024 (Korea Bizwire) – DEBx Medical, an Amsterdam-based pioneering innovator in the field of advanced [...]
ATHENS, Greece, Nov. 13, 2024 (Korea Bizwire) – The European Academy of Allergy and Clinical Immunology (EAACI) is proud to announce the inaugural World Anaphylaxis Awareness Day on 21 November 2024. This landmark initiative, held on the opening day of FAAM-EUROBAT 2024 in Athens, Greece, seeks to raise awareness and promote essential steps in preventing and managing anaphylaxis, a severe, [...]
DECATUR, Ga., Nov. 12, 2024 (Korea Bizwire) – The Mectizan Donation Program applauds Timor-Leste for eliminating lymphatic filariasis (LF) as a public health problem, a remarkable achievement that was recently validated by the World Health Organization (WHO). Timor-Leste is the fifth country in Southeast Asia to achieve this milestone and the first country in the region [...]
Toronto, Nov. 12, 2024 (Korea Bizwire) – Merrithew®, a global leader in mindful movement and the creator of industry-leading education programs such as STOTT PILATES®, ZEN•GA®, Total Barre® and Halo® Training, is pleased to announce the acquisition of T.L. Elliott & Co Ltd, owner of Align-Pilates Equipment Ltd (“Align-Pilates”), a leading brand in Pilates equipment and [...]